Evaluation of appropriate vancomycin prescribing for the prevention of newborn group B streptococcal infections in a community hospital obstetrics service.
Pregnancy
Infant, Newborn
Female
Humans
Vancomycin
/ adverse effects
Obstetrics
Hospitals, Community
Infectious Disease Transmission, Vertical
/ prevention & control
Pregnancy Complications, Infectious
/ drug therapy
Antibiotic Prophylaxis
Streptococcus agalactiae
Streptococcal Infections
/ drug therapy
GBS early onset neonatal infection
group b Streptococcus (GBS)
guidelines
vancomycin
Journal
Journal of perinatal medicine
ISSN: 1619-3997
Titre abrégé: J Perinat Med
Pays: Germany
ID NLM: 0361031
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
28
10
2021
accepted:
16
06
2022
pubmed:
7
7
2022
medline:
11
11
2022
entrez:
6
7
2022
Statut:
epublish
Résumé
The 2019 American College of Obstetricians and Gynecologists (ACOG) guidelines update for the prevention of perinatal group B Clinical pharmacists, in collaboration with an obstetrician, performed this hospital-based study. All instances of intravenous (IV) vancomycin therapy in GBS-positive patients were assessed from 1/1/2018 through 1/1/2021 and compared to the 2010 and 2019 ACOG guidelines. Treatment was analyzed to determine the appropriateness of both indication for use and dosage regimen as co-primary endpoints. Secondary endpoints included renal monitoring parameters, suspected adverse reactions, and early onset GBS disease in newborns, specifically sepsis, meningitis, and/or pneumonia. L&D admissions during the study period included 15,129 patients. All 30 L&D patients who received IV vancomycin for GBS prophylaxis were included in the study. This project demonstrated low compliance to the ACOG guidelines and identified previously unrecognized opportunities for improvement. The low compliance observed in this study, with the exception of documenting GBS status, occurred in spite of hospital adoption of a GBS order set, an updated vancomycin protocol and targeted education of clinical pharmacists. Assessment of the causes of noncompliance identified several potential corrective actions, especially in ordering and monitoring vancomycin.
Identifiants
pubmed: 35794077
pii: jpm-2021-0558
doi: 10.1515/jpm-2021-0558
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1218-1224Informations de copyright
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Références
Berardi, A, Rossi, C, Lugli, L, Creti, R, Bacchi Reggiani, ML, Lanari, M, et al.. M. Group B streptococcus late-onset disease: 2003–2010. Pediatrics 2013;131:e361–8. https://doi.org/10.1542/peds.2012-1231.
ACOG committee opinion. Prevention of group B streptococcal early- onset disease in newborns. Obstet Gynecol 2020;135:e51–72.
Howard, ED. Perinatal management of group B streptococcal infection: clinical update. J Perinat Neonatal Nurs 2019;33:280–2. https://doi.org/10.1097/jpn.0000000000000445.
Money, D, Allen, VM, Yudin, MH, Bouchard, C, Boucher, M, Caddy, S, et al.. The prevention of early-onset neonatal group B streptococcal disease. J Obstet Gynaecol Can 2013;35:939–48. https://doi.org/10.1016/s1701-2163(15)30818-5.
Towers, CV, Weitz, B. Transplacental passage of vancomycin. J Matern Fetal Neonatal Med 2018;31:1021–4. https://doi.org/10.1080/14767058.2017.1306049.
Onwuchuruba, CN, Towers, CV, Howard, BC, Hennessy, MD, Wolfe, L, Brown, MS. Transplacental passage of vancomycin from mother to neonate. Am J Obstet Gynecol 2014;210:352–4. https://doi.org/10.1016/j.ajog.2014.01.019.
Mann, KL, Wu, JY, Shah, SS. Implementation of a pharmacist-driven detailed penicillin allergy interview. Ann Pharmacother 2020;54:364–70. https://doi.org/10.1177/1060028019884874.
Bobb, AM, Payne, TH, Gross, PA. Controversies surrounding use of order sets for clinical decision support in computerized provider order entry. J Am Med Inf Assoc 2007;14:41–7. https://doi.org/10.1197/jamia.m2184.